[go: up one dir, main page]

MX2019008197A - Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. - Google Patents

Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.

Info

Publication number
MX2019008197A
MX2019008197A MX2019008197A MX2019008197A MX2019008197A MX 2019008197 A MX2019008197 A MX 2019008197A MX 2019008197 A MX2019008197 A MX 2019008197A MX 2019008197 A MX2019008197 A MX 2019008197A MX 2019008197 A MX2019008197 A MX 2019008197A
Authority
MX
Mexico
Prior art keywords
tgfß1
permissive
isoform
inhibitors
context
Prior art date
Application number
MX2019008197A
Other languages
English (en)
Inventor
Buckler Alan
J Carven Gregory
Datta Abhishek
Long Kimberly
Schurpf Thomas
Martin Constance
Karla Ashish
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2019008197A publication Critical patent/MX2019008197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Se describen en la presente el uso terapéutico de inhibidores permisivos del contexto, específicos de isoformas de TGFß1 en el tratamiento de enfermedad que implica desregulación de TGFß1.
MX2019008197A 2017-01-06 2018-01-05 Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. MX2019008197A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US201762588626P 2017-11-20 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2019008197A true MX2019008197A (es) 2019-09-11

Family

ID=61198888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008197A MX2019008197A (es) 2017-01-06 2018-01-05 Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.

Country Status (17)

Country Link
US (3) US20180207267A1 (es)
EP (1) EP3551658A1 (es)
JP (3) JP7157744B2 (es)
KR (2) KR20240137126A (es)
CN (2) CN117398457A (es)
AU (2) AU2018205231A1 (es)
BR (1) BR112019013908A2 (es)
CA (1) CA3049005A1 (es)
CL (1) CL2019001874A1 (es)
CO (1) CO2019007298A2 (es)
CR (1) CR20190350A (es)
DO (1) DOP2019000180A (es)
IL (2) IL267790A (es)
MX (1) MX2019008197A (es)
PE (1) PE20191661A1 (es)
PH (1) PH12019501575A1 (es)
WO (1) WO2018129329A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891909A1 (ru) 2016-03-11 2019-02-28 Сколар Рок, Инк. TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
JP7157744B2 (ja) * 2017-01-06 2022-10-20 スカラー ロック インコーポレイテッド アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
AU2019302679A1 (en) 2018-07-11 2021-02-11 Scholar Rock, Inc. High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3689905A3 (en) 2019-01-30 2021-02-24 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta and uses thereof
SG11202110338XA (en) * 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
MY204791A (en) 2019-08-28 2024-09-13 Chugai Pharmaceutical Co Ltd Cross-species anti-latent tgf-beta 1 antibodies and methods of use
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
US20230050148A1 (en) * 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2021205433A1 (en) * 2020-01-11 2022-08-18 Scholar Rock, Inc. Tgfß inhibitors and use thereof
PH12022552500A1 (en) 2020-03-26 2024-03-25 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195485A1 (en) * 2020-03-27 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20210395344A1 (en) 2020-04-27 2021-12-23 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CA3198003A1 (en) * 2020-12-02 2022-06-09 Jiin-Tarng WANG Anti-garp/tgf? antibodies and methods of use
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4337654A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240301073A1 (en) 2021-07-14 2024-09-12 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
CN117957013A (zh) * 2021-08-11 2024-04-30 Hcw生物科技公司 多链嵌合多肽及其在肝脏疾病治疗中的用途
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CR20240386A (es) 2022-03-17 2024-10-24 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos
CN119255993A (zh) 2022-03-22 2025-01-03 奥托泰利克生物公司 噻唑衍生物化合物及其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
EP4698533A1 (en) 2023-04-21 2026-02-25 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117721079B (zh) * 2024-01-26 2025-03-11 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1997035991A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
WO2002002773A2 (en) 2000-06-29 2002-01-10 Abbott Laboratories Dual specificity antibodies and methods of making and using
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MX2007009545A (es) 2005-02-08 2008-03-11 Genzyme Corp Anticuerpos para tgfbeta.
LT2125894T (lt) * 2007-03-22 2019-03-25 Biogen Ma Inc. Prisijungiantys baltymai, įskaitant antikūnus, antikūno dariniai ir antikūno fragmentai, kurie specifiškai suriša cd154, ir jų panaudojimas
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
RU2563830C2 (ru) * 2011-02-08 2015-09-20 Эббви Инк. Лечение остеоартрита и боли
KR102148982B1 (ko) * 2011-06-03 2020-08-27 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
KR20140076602A (ko) * 2011-11-08 2014-06-20 화이자 인코포레이티드 항-m-csf 항체를 사용한 염증성 장애의 치료 방법
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
PT2981822T (pt) * 2013-05-06 2020-12-07 Scholar Rock Inc Composições e métodos para modulação do fator de crescimento
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2016206682B2 (en) * 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
EA201891909A1 (ru) 2016-03-11 2019-02-28 Сколар Рок, Инк. TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
JP7157744B2 (ja) * 2017-01-06 2022-10-20 スカラー ロック インコーポレイテッド アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用

Also Published As

Publication number Publication date
US20190209682A1 (en) 2019-07-11
PH12019501575A1 (en) 2019-11-04
JP7157744B2 (ja) 2022-10-20
AU2025203555A1 (en) 2025-06-05
US20180207267A1 (en) 2018-07-26
IL304416A (en) 2023-09-01
KR20240137126A (ko) 2024-09-19
CN110382530A (zh) 2019-10-25
CN117398457A (zh) 2024-01-16
CR20190350A (es) 2019-11-15
PE20191661A1 (es) 2019-11-11
KR20190098255A (ko) 2019-08-21
WO2018129329A1 (en) 2018-07-12
US20240016928A1 (en) 2024-01-18
JP2020503362A (ja) 2020-01-30
JP2022188226A (ja) 2022-12-20
BR112019013908A2 (pt) 2020-02-04
EP3551658A1 (en) 2019-10-16
CL2019001874A1 (es) 2019-12-06
AU2018205231A1 (en) 2019-07-18
CA3049005A1 (en) 2018-07-12
CO2019007298A2 (es) 2019-07-31
JP2025000891A (ja) 2025-01-07
IL267790A (en) 2019-09-26
DOP2019000180A (es) 2019-09-15

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
LT3902803T (lt) Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
MY187540A (en) Compounds active towards bromodomains
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
PH12016501838A1 (en) Compounds and their methods of use
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
LT3630112T (lt) Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui
TW201613926A (en) Inhibitors of bruton's tyrosine kinase